Inhibikase Therapeutics (NASDAQ: IKT) net income
Inhibikase Therapeutics reported a net loss of $48.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $27.5m. Earnings per share were −$0.49.
Inhibikase Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$48.3m | — | — | −$0.49 |
| 2024 | −$27.5m | — | — | −$1.16 |
| 2023 | −$19.0m | — | −7,304.7% | −$3.57 |
| 2022 | −$18.1m | — | −14,625.9% | −$0.72 |
| 2021 | −$14.8m | — | −476.9% | −$0.81 |
| 2020 | −$2.8m | — | −407.7% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Inhibikase Therapeutics net income compared with its sector
By net income for its latest fiscal year, Inhibikase Therapeutics ranks 252nd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 250th | Precision Biosciences | −$45.7m | −133.4% |
| 251st | Anavex Life Sciences | −$46.4m | — |
| 252nd | Inhibikase Therapeutics | −$48.3m | — |
| 253rd | Shattuck Labs | −$48.8m | −4,880.9% |
| 254th | Septerna | −$48.9m | −106.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Inhibikase Therapeutics
- How much did Inhibikase Therapeutics earn in fiscal 2025?
- Inhibikase Therapeutics reported a net loss of $48.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $27.5m.
- What are the earnings per share of Inhibikase Therapeutics?
- They were −$0.49 in fiscal 2025, compared with −$1.16 in fiscal 2024.
- Where does Inhibikase Therapeutics rank in its sector by net income?
- It ranks 252nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Inhibikase Therapeutics come from?
- From the annual report (Form 10-K) that Inhibikase Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Inhibikase Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Inhibikase Therapeutics: the Inhibikase Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.